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Abstract
Introduction: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for
BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight
additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1),
rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2).
Methods: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer
risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers
and analysed the associations with breast cancer risk within a retrospective likelihood framework.
Results: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele
hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 × 10-4). The association was restricted to mutations proven or
predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 × 10-5, P-difference =
0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015;
rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly
associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to
0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2
mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
Conclusions: The present findings, in combination with previously identified modifiers of risk, will ultimately lead
to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2
mutation carriers.
Introduction
Pathogenic mutations in BRCA1 and BRCA2 confer high
risks of breast and ovarian cancers [1,2]. Several lines of
evidence suggest that these risks are modified by other
genetic or environmental factors that cluster in families.
Direct evidence for genetic modifiers of risk has been
provided through studies that investigated the associa-
tions between common breast and ovarian cancer sus-
ceptibility variants, identified through genome-wide
association studies (GWAS) or candidate gene studies in
the general population, and cancer risk for BRCA1 and
BRCA2 mutation carriers [3-8] and through GWAS in
BRCA1 and BRCA2 mutation carriers [9-11]. Six loci (at
TOX3, 2q35, 6q25.1, 19p13, CASP8 and wild-type copy
of BRCA1) are now known to be associated with breast
cancer risk for BRCA1 mutation carriers; a further 10
loci (at FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7,
5p12, 1p11.2, ZNF365 and RAD51) have been associated
with breast cancer risk for BRCA2 carriers. The associa-
tion patterns between these common variants and breast
cancer risk for BRCA1 and BRCA2 mutation carriers are
in general different, and mostly reflect differences in the
associations of these single-nucleotide polymorphism
(SNPs) with estrogen receptor (ER) status of breast can-
cer [12-14].
GWAS in the general population have recently identi-
fied eight additional breast cancer susceptibility loci
which have not been previously investigated in BRCA1
and BRCA2 mutation carriers. Turnbull et al. [15] iden-
tified five susceptibility loci on chromosomes 9
(rs1011970), 10 (rs2380205, rs10995190, rs704010) and
11 (rs614367) through a GWAS of breast cancer cases
with a family history of the disease and unrelated con-
trols. In a further follow-up of additional promising
associations from that GWAS, the Breast Cancer Asso-
ciation Consortium (BCAC) has identified two addi-
tional loci at 12p11 (rs10771399) and 12q24 (rs1292011)
which were associated with breast cancer risk in the
general population [16]. The estimated odds ratios (OR)
for ER-positive breast cancer for four of these SNPs
(rs1011970 near CDKN2A/CDKN2B at chromosome 9,
rs10995190 in ZNF365 at chromosome 10, rs614367 at
11q13 and rs1292011 at 12q24) were higher than the
OR estimates for ER-negative breast cancer. In contrast,
the OR estimates were similar for ER-positive and ER-
negative breast cancer for SNPs rs2380205 (near
ANKRD16 and FBXO18), rs704010 (upstream of
ZMIZ1) and rs10771399 near PTHLH. In a separate
GWAS that included mainly cases with two primary
breast cancers or a family history of the disease, SNP
rs865686 at 9q31.2 was found to be associated with risk
for breast cancer, OR = 0.89 (95% CI: 0.85 to 0.92), but
no estimates by ER status were reported [17].
The associations of these eight loci with breast cancer
risk for BRCA1 and BRCA2 mutation carriers are still
unknown. To evaluate these associations, we genotyped
the eight SNPs in BRCA1 and BRCA2 mutation carriers
participating in the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA). We further investi-
gated the associations with the risks of developing ER-
positive and ER-negative breast cancer and the risk of
ovarian cancer.
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 2 of 18
Materials and methods
Subjects
All carriers participated in clinical or research studies at
the host institutions which have been approved by local
ethics committees (list provided in Additional file 1
Table S1). Informed consent was obtained from all
study participants. Subjects were BRCA1 and BRCA2
mutation carriers recruited by 40 study centres in 28
countries through CIMBA (Additional file 1 Table 2).
The majority of carriers (97.58%) were recruited through
cancer genetics clinics offering genetic testing, and
enrolled into national or regional studies. Some carriers
were identified by population-based sampling of cases
(2.38%), and some by community recruitment (0.04%).
Eligibility to participate in CIMBA is restricted to female
carriers of pathogenic BRCA1 or BRCA2 mutations age
18 years old or older at recruitment. Information col-
lected included the year of birth; mutation description,
including nucleotide position and base change; self
reported ethnic ancestry, age at last follow-up; ages at
breast or ovarian cancer diagnoses; and age or date at
bilateral prophylactic mastectomy and oophorectomy.
Related individuals were identified through a unique
family identifier. Women were included in the analysis if
they carried mutations that were pathogenic according
to generally recognized criteria [18]. Further details on
CIMBA can be found elsewhere [19].
Women who carried pathogenic mutations in both
BRCA1 and BRCA2 were excluded from the current
analysis. The primary analysis was restricted to women
self-reported as “white of European ancestry”. The num-
ber of mutation carriers of non-white ancestry was too
small to allow separate analysis. We investigated possi-
ble overlap of carriers between studies by comparing the
year of birth, exact mutation description and the
reported ages, to identify potential duplicate individuals.
Where possible we also used other genotype data on
SNPs genotyped in the current round (at least 26 SNPs),
in previous genotyping rounds or as part of GWAS to
find hidden duplicates. When a potential duplicate was
identified, we contacted the relevant centres for further
information about these individuals, in a manner that
protected the identity of the individuals in question, in
order to determine precisely the extent of true overlap
in subjects and families appearing more than once in
the data set. Duplicate mutation carriers were included
only once in the analysis. When in doubt, and when
centres could not clarify a potential duplication, one of
the samples was excluded from the analysis.
Genotyping
DNA samples (in almost all cases, obtained from blood)
were genotyped using the iPLEX Mass Array platform at
four genotyping centres (Additional file 1 Table S2); the
iPLEX included 26 SNPs as part of a larger study. All
centres included at least 2% of the samples in duplicate,
no template controls in every plate, and a random mix-
ture of affected and unaffected carriers. Samples that
failed for ≥ 20% of all the SNPs typed (that is, five or
more) were excluded from the analysis. A study was
included in the analysis only if the call rate was over
95%, after samples that failed at multiple SNPs had been
excluded. For each study, genotypes for at least 98% of
the duplicate samples had to be concordant. To assess
the accuracy of genotyping across genotyping centres,
the four centres genotyped 95 DNA samples from a
standard test plate (Coriell Institute) for all SNPs. If the
genotyping was inconsistent for more than one sample
in the test plate, all the studies genotyped at the centre
were excluded from the analysis of that SNP. No SNPs
failed this criterion. The present study included eight
SNPs: rs1011970 (9p21, near CDKN2A/B), rs10995190
(10q21, near ZNF365), rs704010 (10q22, near ZMIZ1),
rs2380205 (10p15), rs614367 (11q13), rs1292011
(12q24), rs10771399 (12p11 near PTHLH) and rs865686
(9q31.2). Based on the quality control criteria, 4 studies
were excluded from the analysis of rs2380205 (one due
to low duplicate concordance, 3 due to low call rate), 2
studies were excluded from the analysis of rs704010
(low call rate) and 13 studies were excluded from the
analysis of rs1292011 (all due to low call rates). As an
additional genotyping quality-control check, we also
evaluated the deviation from Hardy-Weinberg equili-
brium (HWE) for unrelated subjects separately for each
SNP and study. Nine studies had HWE P-values in the
range 0.005 to 0.05 (two studies for rs10995190, two
studies for rs704010, one study for rs10771399, two for
rs1292011 and two for rs865686). Upon examination of
the cluster plots for these studies and SNPs, none
revealed any unusual patterns and these studies were
included in all the analyses. After the above exclusions,
a total of 19,731 unique mutation carriers (12,599
BRCA1 and 7,132 BRCA2) from 40 studies had an
observed genotype for at least 1 of the SNPs and were
included in the primary analysis.
Statistical analysis
The aim of the primary analysis was to evaluate the
association between each genotype and breast cancer
risk within a survival analysis framework. The time vari-
able for each individual was defined to be the time to
breast cancer diagnosis. Each individual was followed
until the first breast cancer diagnosis, ovarian cancer
diagnosis, or bilateral prophylactic mastectomy or the
age at last observation. Only those with a first breast
cancer diagnosis were considered as affected in the
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analysis. Mutation carriers censored at ovarian cancer
diagnosis were considered unaffected. Analysis was con-
ducted by modelling the retrospective likelihood of the
observed genotypes conditional on the disease pheno-
types as previously described [18]. The effect of each
SNP was modelled either as a per-allele hazard ratio
(HR) (multiplicative model) or as separate HRs for het-
erozygotes and homozygotes, and these were estimated
on the logarithmic scale. The HRs were assumed to be
independent of age (that is, we used a Cox propor-
tional-hazards model). The assumption of proportional
hazards was tested by adding a “genotype x age” interac-
tion term to the model in order to fit models in which
the HR changed with age. Analyses were carried out
with the pedigree-analysis software MENDEL [20];
details of this approach have been described previously
[18,21]. We examined between-study heterogeneity by
comparing the models that allowed for study-specific
log-hazard ratios against models in which the same log-
hazard ratio was assumed to apply to all studies.
To investigate whether our results were influenced by
any of our assumptions we performed additional sensi-
tivity analyses. If a SNP is associated with disease survi-
val, the inclusion of prevalent cases may influence the
HR estimates. Current data indicate that five-year survi-
val after a breast cancer diagnosis is over 80% (Cancer
Research - UK, Breast cancer survival statistics) and stu-
dies have suggested no difference in survival between
mutation carriers and non-carriers [22]. We, therefore,
repeated our analysis by excluding mutation carriers
diagnosed more than five years prior to recruitment into
the study. To examine whether SNP associations dif-
fered by type of mutation, we classified BRCA1 muta-
tions according to their potential functional effect
[23-26]. Class 1 mutations were those likely to lead to
the absence of protein expression due to i) reduced
transcript level and/or degradation or instability of trun-
cated proteins, or ii) absence of transcription. Class 1
mutations comprise truncating mutations expected to
trigger nonsense-mediated mRNA decay (NMD) or
translation re-initiation but no production of stable pro-
tein, and deletion of transcription regulatory regions.
Class 2 mutations were those likely to generate stable
mutant proteins with partial or total loss of function
that might also have dominant negative effect. Class 2
mutations include missense substitutions, in-frame dele-
tions and insertions, as well as truncating mutations
with premature stop codons occurring in the last exon.
Mutations whose consequences at transcript or protein
level could not be inferred were not considered for this
classification. These were mainly mutations located in
splice sites but not characterised for their effect at the
transcript level, or large deletions or insertions with
undetermined boundaries.
The associations of these SNPs with ovarian cancer
risk were evaluated within a competing risk analysis fra-
mework [8,9,21], by estimating HRs simultaneously for
breast and ovarian cancers. In this model, each indivi-
dual was at risk of developing either breast or ovarian
cancer, by assuming that the probabilities of developing
each disease were independent conditional on the
underlying genotype. A different censoring process was
used for the competing risk analysis, whereby indivi-
duals were followed up to the age of the first breast or
ovarian cancer diagnosis and were considered to have
developed the corresponding disease. No follow-up was
considered after the first cancer diagnosis. Individuals
were censored for breast cancer at the age of bilateral
prophylactic mastectomy and for ovarian cancer at the
age of bilateral oophorectomy and were assumed to be
unaffected for the corresponding disease. The remaining
individuals were censored at the age at last observation
and were assumed to be unaffected for both diseases.
We further evaluated the associations of these SNPs with
breast cancer subtypes defined by the estrogen receptor
(ER) status of the tumours in BRCA1 and BRCA2 mutation
carriers. The analysis was carried out by an extension of
the retrospective likelihood approach to model the simulta-
neous effect of each SNP on more than one tumour sub-
type [14]. Briefly, this involves modelling the conditional
likelihood of the observed SNP genotypes and tumour sub-
types, given the disease phenotypes. Within this framework
it is possible to estimate simultaneously the HRs for each
tumour subtype and test for heterogeneity in the associa-
tions. Only studies that provided tumour pathology infor-
mation and had genotype information were included in the
analysis. To maximise the available information, genotyped
mutation carriers that were missing information on
tumour characteristics (within each study) were included
in the analysis, and their disease subtype was assumed to
be missing at random [14]. This is a reasonable assumption
given that more than 90% of mutation carriers in our sam-
ple were recruited prior to 2007, when it was uncommon
to use tumour pathology in selecting individuals for
BRCA1 and BRCA2 mutation screening.
To ensure a sufficiently large number of mutation car-
riers within each stratum, we grouped studies from the
same country. All analyses were stratified by country of
residence and used calendar-year- and cohort-specific
cancer incidences for BRCA1 and BRCA2 [27]. For sen-
sitivity analyses, strata with small numbers of mutation
carriers were grouped. We used a robust variance-esti-
mation approach to allow for the non-independence
among related carriers [28].
Results
The analysis included 12,599 BRCA1 and 7,132 BRCA2
mutation carriers who were genotyped successfully for
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at least one of the eight SNPs. Table 1 summarises the
characteristics of the mutation carriers used in the ana-
lysis. In evaluating associations with breast cancer,
10,200 mutation carriers had been diagnosed with a first
breast cancer diagnosis, 1,869 were censored at an ovar-
ian cancer diagnosis, 561 at age of bilateral prophylactic
mastectomy and 7,101 at the age at last observation.
Associations with cancer risk for BRCA1 mutation carriers
Of the eight SNPs, only rs10771399 in PTHLH was
associated with breast cancer risk for BRCA1 mutation
carriers (P-trend = 3 × 10-4, Table 2). The association
was consistent with a multiplicative model in which
each copy of the minor allele was estimated to confer a
HR of 0.87 (95% CI: 0.81 to 0.94). There was no evi-
dence of heterogeneity in the HR estimates across stu-
dies (P-het = 0.24, Additional file 1 Supplementary
Figure 1). There was no evidence that the HRs varied
with age (P = 0.68). The association remained signifi-
cant, with a similar HR estimate (HR = 0.85, 95% CI:
0.77 to 0.93, P-trend = 6 × 10-4, Table 3), when long-
term survivors were excluded from the analysis, suggest-
ing no evidence of survival bias. Interestingly, the asso-
ciation was restricted to BRCA1 carriers of Class 1
mutations (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3
× 10-5, Table 3) with no evidence of association for
Class 2 mutation carriers (HR = 1.00, 0.87 to 1.15, P-
trend = 0.99, P-difference between Class 1 and Class 2
= 0.03).
We found no evidence of association between breast
cancer risk for BRCA1 mutation carriers and any of
the other SNPs under the trend models (P-trend >
0.15). There was, however, some suggestion of an asso-
ciation under the genotype specific model for rs865686
(2df P = 0.06, Table 2), reflecting a lower HR for het-
erozygous carriers than for either homozygote geno-
type. There was marginal evidence of heterogeneity in
the HRs across countries for rs704010 and rs865686
(P-het = 0.04 for both), but examination of the forest
plots revealed that in each case this was mainly due to
a single study/country of relatively small sample size,
with the majority of the HR estimates being close to 1
(Additional file 1 Supplementary Figure 1). There was
no evidence that the HRs varied by age for any of the
SNPs (P > 0.08 for all).
We further evaluated the SNP associations with
breast and ovarian cancer risk simultaneously (Table
4). The associations with breast cancer risk remained
Table 1 Summary characteristics for the 19731 eligible BRCA1 and BRCA2 carriers* used in the analysis
Characteristic BRCA1 BRCA2
Unaffected Breast cancer Unaffected Breast cancer
Number 6,209 6,390 3,322 3,810
Person-years follow-up 264,903 263,068 147,053 168,201
Median age at censure (IQR1) 42 (34 to 50) 40 (34 to 47) 43 (34 to 53) 43 (37 to 50)
Age at censure, N (%)
< 30 1,189 (19.2) 691 (10.8) 611 (18.4) 306 (8.0)
30 to 39 1,161 (26.8) 2,445 (38.3) 834 (25.1) 1,141 (30.0)
40 to 49 1,765 (28.4) 2,191 (34.3) 865 (26.0) 1,394 (36.6)
50 to 59 1,058 (17.0) 812 (12.7) 566 (17.0) 687 (18.0)
60 to 69 380 (6.1) 198 (3.1) 302 (9.1) 226 (5.9)
70+ 156 (2.5) 53 (0.8) 144 (4.3) 56 (1.5)
Year of birth, N (%)
< 1920 28 (0.5) 30 (0.5) 23 (0.7) 44 (1.2)
1920 to 1929 131 (2.1) 196 (3.1) 99 (3.0) 167 (4.4)
1930 to 1939 369 (5.9) 516 (8.1) 232 (7.0) 430 (11.3)
1940 to 1949 832 (13.4) 1,341 (21.0) 458 (13.8) 896 (23.5)
1950 to 1959 1,409 (22.7) 1,989 (31.1) 691 (20.8) 1,160 (30.5)
1960 to 1969 1,703 (27.4) 1,666 (26.1) 902 (27.2) 868 (22.8)
1970+ 1,737 (28.0) 652 (10.2) 917 (27.6) 245 (6.4)
Mutation Class, N (%)
Class 12 4,063 (65.4) 3,878 (60.7) 3,114 (93.7) 3,520 (92.4)
Class 22 1,780 (28.7) 1,973 (30.9) 72 (2.2) 100 (2.6)
Other 366 (5.9) 539 (8.4) 136 (4.1) 190 (5.0)
1 IQR: Interquartile Range
2 See methods for definitions
* Carriers of self-reported white European ancestry only.
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 5 of 18
Table 2 SNP genotype distributions and associations with breast cancer risk.
Mutation Genotype Unaffected
N (%)
Affecteda
N (%)
HR 95% CI P-value
CDK2NA/B - rs1011970
BRCA1 GG 4,318 (69.7) 4,460 (70.0) 1
GT 1,698 (27.4) 1,719 (27.0) 1.01 0.94 to 1.09
TT 180 (2.9) 195 (3.1) 1.11 0.91 to 1.35
2-df test 0.61
per allele 1.03 0.96 to 1.09 0.45
BRCA2 GG 2,279 (68.7) 2,586 (67.9) 1
GT 943 (28.4) 1,098 (28.9) 1.08 0.98 to 1.19
TT 94 (2.8) 123 (3.2) 1.23 0.95 to 1.59
2-df test 0.12
per allele 1.09 1.00 to 1.18 0.048
ZNF365 - rs10995190
BRCA1 GG 4,394 (70.9) 4,556 (71.5) 1
GA 1,656 (26.7) 1,662 (26.1) 0.98 0.91 to 1.06
AA 147 (2.4) 156 (2.5) 0.98 0.79 to 1.20
2-df test 0.89
per allele 0.99 0.93 to 1.05 0.64
BRCA2 GG 2,334 (70.4) 2,802 (73.7) 1
GA 913 (27.5) 923 (24.3) 0.86 0.78 to 0.96
AA 68 (20.1) 79 (2.1) 0.96 0.69 to 1.34
2-df test 0.019
per allele 0.90 0.82 to 0.98 0.015
ZMIZ1 - rs704010
BRCA1 CC 2,476 (40.3) 2,504 (39.8) 1
CT 2,814 (45.8) 2,894 (46.0) 1.03 0.96 to 1.10
TT 855 (13.9) 888 (14.1) 1.04 0.93 to 1.15
2-df test 0.69
per allele 1.02 0.97 to 1.07 0.42
BRCA2 CC 1,286 (39.3) 1,443 (38.4) 1
CT 1,496 (45.7) 1,779 (47.3) 1.07 0.97 to 1.18
TT 494 (15.8) 539 (14.3) 0.99 0.86 to 1.14
2-df test 0.32
per allele 1.01 0.95 to 1.08 0.73
10p15 - rs2380205
BRCA1 CC 1,609 (32.5) 1,710 (32.1) 1
CT 2,410 (48.7) 2,625 (49.3) 1.01 0.93 to 1.09
TT 933 (18.8) 990 (18.6) 1.02 0.92 to 1.13
2-df test 0.95
per allele 1.01 0.96 to 1.06 0.75
BRCA2 CC 1,013 (32.8) 1,163 (31.8) 1
CT 1,516 (49.1) 1,816 (49.7) 1.05 0.95 to 1.16
TT 560 (18.1) 681 (18.6) 1.03 0.90 to 1.17
2-df test 0.63
per allele 1.02 0.96 to 1.09 0.57
11q13 - rs614367
BRCA1 CC 4,516 (73.2) 4,581 (72.1) 1
CT 1,511 (24.5) 1,618 (25.5) 1.05 0.98 to 1.14
TT 146 (2.4) 154 (2.4) 1.07 0.87 to 1.32
2-df test 0.34
per allele 1.05 0.98 to 1.12 0.15
BRCA2 CC 2,432 (73.6) 2,723 (71.8) 1
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essentially unchanged in the competing risk analysis,
with only the PTHLH SNP rs10771399 being signifi-
cantly associated with breast cancer risk. There was
some suggestion of a possible association between this
SNP and ovarian cancer risk for BRCA1 mutation car-
riers with risk in the opposite direction (HR for ovar-
ian cancer = 1.14, 95% CI: 1.00 to 1.30, P-trend =
0.06) especially among rare homozygotes (ovarian can-
cer HR for GG = 1.67, 95% CI: 1.05 to 2.64, P-homo-
zygotes = 0.03). This analysis also provided some weak
evidence for an association between SNP rs614367 at
11q13 and ovarian cancer risk for BRCA1 mutation
carriers under the genotype-specific model (2df P-
value = 0.03). There was no evidence that any of the
other SNPs are associated with ovarian cancer risk for
BRCA1 mutation carriers.
Associations with cancer risk for BRCA2 mutation carriers
There was evidence of association with breast cancer
risk for BRCA2 mutation carriers for four SNPs (Table
2). The minor allele of rs10995190 in ZNF365 was asso-
ciated with a reduced risk of breast cancer, where each
copy of allele “A” was estimated to confer a HR of 0.90
(95% CI: 0.82 to 0.98, P-trend = 0.015). There was also
Table 2 SNP genotype distributions and associations with breast cancer risk. (Continued)
CT 799 (24.1) 983 (26.0) 1.06 0.96 to 1.17
TT 76 (2.3) 83 (2.2) 0.97 0.72 to 1.30
2-df test 0.54
per allele 1.03 0.95 to 1.12 0.46
12q24 - rs1292011
BRCA1 AA 1,292 (34.3) 1,331 (35.4) 1
AG 1,825 (48.4) 1,775 (47.3) 0.98 0.89 to 1.07
GG 653 (17.3) 649 (17.3) 1.01 0.90 to 1.14
2-df test 0.80
per allele 1.00 0.94 to 1.06 0.99
BRCA2 AA 824 (35.2) 908 (35.9) 1
AG 1,095 (46.7) 1,225 (48.4) 1.03 0.92 to 1.16
GG 423 (18.1) 397 (15.7) 0.84 0.72 to 0.99
2-df test 0.03
per allele 0.94 0.87 to 1.01 0.10
PTHLH - rs10771399
BRCA1 AA 4,913 (79.4) 5,221 (82.0) 1
AG 1,194 (19.3) 1,082 (17.0) 0.87 0.80 to 0.95
GG 83 (1.3) 65 (1.0) 0.77 0.57 to 1.04
2-df test 1.5 × 10-3
per allele 0.87 0.81 to 0.94 3.2 × 10-4
BRCA2 AA 2,649 (80.0) 3,085 (81.2) 1
AG 620 (18.7) 679 (17.9) 0.95 0.85 to 1.07
GG 45 (1.4) 34 (0.9) 0.74 0.47 to 1.15
2-df test 0.31
per allele 0.93 0.84 to 1.04 0.20
9q31.2 - rs865686
BRCA1 TT 2,521 (40.1) 2,640 (41.4) 1
TG 2,872 (46.4) 2,849 (44.7) 0.95 0.88 to 1.01
GG 799 (12.9) 880 (13.8) 1.05 0.95 to 1.17
2-df test 0.06
per allele 1 0.96 to 1.05 0.85
BRCA2 TT 1,277 (38.6) 1,581 (41.6) 1
TG 1,610 (48.6) 1,717 (45.2) 0.86 0.78 to 0.95
GG 425 (12.8) 501 (13.2) 0.96 0.84 to 1.11
2-df test 7.3 × 10-3
per allele 0.95 0.89 to 1.01 0.10
a Breast Cancer
HR, hazard ratio
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Table 3 Associations with breast cancer risk, after excluding prevalent breast cancer cases, and BRCA1 mutation class.
Unaffected, N Affected, N HR 95% CI P-value
Excluding prevalent breast cancer cases
CDK2NA/B -rs1011970
BRCA1 6,200 3,152 1.05 0.98 to 1.14 0.18
BRCA2 3,319 1,950 1.10 1.00 to 1.22 0.05
ZNF365 - rs10995190
BRCA1 6,201 3,151 0.96 0.89 to 1.04 0.34
BRCA2 3,318 1,949 0.90 0.81 to 1.00 0.05
ZMIZ1 - rs704010
BRCA1 6,149 3,094 1.02 0.96 to 1.08 0.53
BRCA2 3,276 1,919 0.98 0.91 to 1.06 0.64
10p15 - rs2380205
BRCA1 4,955 2,764 1.02 0.95 to 1.08 0.64
BRCA2 3,092 1,884 1.00 0.93 to 1.08 0.92
11q13 - rs614367
BRCA1 6,177 3,144 1.01 0.94 to 1.10 0.73
BRCA2 3,310 1,944 0.99 0.89 to 1.10 0.88
12q24 - rs1292011
BRCA1 3,773 1,798 1.04 0.97 to 1.12 0.29
BRCA2 2,345 1,220 0.96 0.88 to 1.06 0.41
PTHLH - rs10771399
BRCA1 6,194 3,152 0.85 0.77 to 0.93 5.8 × 10-4
BRCA2 3,317 1,944 0.89 0.78 to 1.00 0.06
9q31.2 - rs865686
BRCA1 6,196 3,149 1.01 0.95 to 1.07 0.72
BRCA2 3,315 1,946 0.94 0.87 to 1.02 0.15
BRCA1 analysis by mutation class
CDK2NA/B -rs1011970
Class1 4,040 3,843 1.01 0.94 to 1.10 0.72
Class2 1,771 1,958 1.03 0.91 to 1.16 0.66
ZNF365 - rs10995190
Class1 4,058 3,844 .99 0.92 to 1.07 0.80
Class2 1,774 1,957 0.97 0.86 to 1.09 0.59
ZMIZ1 - rs704010
Class1 3,998 3,787 1.04 0.98 to 1.10 0.22
Class2 1,767 1,936 1.01 0.92 to 1.11 0.85
10p15 - rs2380205
Class1 3,664 3,538 1.01 0.95 to 1.07 0.82
Class2 931 1,263 1.03 0.91 to 1.15 0.67
11q13 - rs614367
Class1 4,024 3,833 1.10 1.02 to 1.19 0.02
Class2 1,764 1,948 0.94 0.84 to 1.06 0.32
12q24 - rs1292011
Class1 2,812 2,521 0.99 0.92 to 1.06 0.71
Class2 642 797 0.97 0.84 to 1.12 0.68
PTHLH - rs10771399
Class1 4,035 3,841 0.82 0.74 to 0.90 3.1 × 10-5
Class2 1,770 1,953 1.00 0.87 to 1.15 0.99
9q31.2 - rs865686
Class1 4,038 3,840 0.98 0.92 to 1.04 0.48
Class2 1,769 1,957 1.03 0.94 to 1.14 0.49
HR, hazard ratio
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Table 4 Competing risk analysis*.
Breast cancer Ovarian cancer
Unaffected
N (%)
Breast
cancer
N (%)
Ovarian
cancer
N (%)
HR 95% CI P-value HR 95% CI P-value
CDK2NA/B - rs1011970
BRCA1 GG 3,328 (69.6) 4,424 (69.9) 1,026 (70.1) 1 1
GT 1,309 (27.4) 1,710 (27.0) 398 (27.2) 1.03 0.95 to 1.11 1.10 0.95 to 1.26
TT 142 (3.0) 194 (3.1) 39 (2.7) 1.09 0.88 to 1.35 0.90 0.61 to 1.32
2-df test 0.57 0.35
per allele 1.04 0.91 to 1.11 0.30 1.04 0.93 to 1.17 0.48
BRCA2 GG 1,972 (68.6) 2578 (67.9) 315 (69.5) 1 1
GT 815 (28.4) 1097 (28.9) 129 (28.5) 1.09 0.98 to 1.21 1.07 0.85 to 1.35
TT 86 (3.0) 122 (3.2) 9 (2.0) 1.19 0.91 to 1.57 0.84 0.40 to 1.77
2-df test 0.15 0.74
per allele 1.09 1.00 to 1.19 0.05 1.03 0.84 to 1.25 0.81
ZNF365 - rs10995190
BRCA1 GG 3,408 (71.3) 4,523 (71.5) 1,019 (69.6) 1 1
GA 1,258 (26.3) 1,650 (26.1) 410 (28.0) 1.00 0.93 to 1.08 1.12 0.98 to 1.28
AA 113 (2.4) 155 (2.5) 35 (2.4) 0.96 0.78 to 1.20 0.90 0.61 to 1.33
2-df test 0.94 0.23
per allele 0.99 0.93 to 1.06 0.88 1.06 0.95 to 1.19 0.32
BRCA2 GG 2,033 (70.4) 2,795 (73.7) 318 (70.2) 1 1
GA 794 (27.7) 920 (24.3) 122 (26.9) 0.86 0.78 to 0.96 0.99 0.78 to 1.25
AA 55 (1.9) 79 (2.1) 13 (2.9) 1.03 0.74 to 1.43 1.58 0.83 to 3.03
2-df test 0.02 0.37
per allele 0.90 0.82 to 0.99 0.03 1.06 0.87 to 1.31 0.55
ZMIZ1 - rs704010
BRCA1 CC 1,904 (40.2) 2,493 (40.0) 583 (40.1) 1 1
CT 2,172 (45.9) 2,871 (46.0) 665 (45.7) 1.02 0.95 to 1.10 1.01 0.89 to 1.15
TT 660 (13.9) 877 (14.1) 206 (14.2) 1.02 0.92 to 1.14 1.01 0.84 to 1.22
2-df test 0.67 0.99
per allele 1.01 0.97 to 1.07 0.58 1.01 0.92 to 1.10 0.90
BRCA2 CC 1,109 (39.0) 1,439 (38.4) 181 (40.1) 1 1
CT 1,306 (46.0) 1,774 (47.3) 192 (43.4) 1.06 0.96 to 1.17 0.96 0.76 to 1.20
TT 426 (15.0) 538 (14.3) 69 (15.6) 1.00 0.86 to 1.15 1.05 0.77 to 1.43
2-df test 0.46 0.81
per allele 1.01 0.95 to 1.08 0.72 1.01 0.87 to 1.18 0.90
10p15 - rs2380205
BRCA1 CC 1,183 (32.2) 1,698 (32.1) 438 (33.2) 1 1
CT 1,796 (48.9) 2,605 (49.3) 634 (48.1) 0.99 0.91 to 1.08 0.91 0.79 to 1.05
TT 696 (18.9) 981 (18.6) 246 (18.7) 1.00 0.90 to 1.12 0.94 0.78 to 1.14
2-df test 0.96 0.45
per allele 1.00 0.95 to 1.06 0.98 0.96 0.87 to 1.06 0.40
BRCA2 CC 872 (32.6) 1,161 (31.8) 143 (33.7) 1 1
CT 1,321 (49.4) 1,812 (49.6) 199 (46.9) 1.04 0.94 to 1.16 0.94 0.74 to 1.19
TT 481 (18.0) 678 (18.6) 82 (19.3) 1.03 0.90 to 1.18 1.01 0.75 to 1.38
2-df test 0.74 0.82
per allele 1.02 0.95 to 1.09 0.61 1.00 0.85 to 1.16 0.98
11q13 - rs614367
BRCA1 CC 3,439 (72.3) 4,547 (72.1) 1,111 (76.2) 1 1
CT 1,212 (25.5) 1,606 (25.5) 311 (21.3) 1.02 0.94 to 1.11 0.83 0.72 to 0.96
TT 109 (2.3) 154 (2.4) 37 (2.5) 1.12 0.91 to 1.39 1.20 0.81 to 1.76
2-df test 0.52 0.03
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some marginal evidence that the minor allele of
rs1011970 near CDKN2A/CDKN2B was associated with
increased breast cancer risk (HR = 1.09, 95% CI: 1.00 to
1.18, P-trend = 0.048). None of the other polymorph-
isms was associated with breast cancer risk for BRCA2
mutation carriers under the multiplicative model. How-
ever, SNPs rs865686 and rs1292011 were associated
with risk under the genotype specific model (2df-P =
0.007 and 0.03 respectively, Table 2). There was some
evidence of heterogeneity in the HRs across countries
for rs1011970 (P-het = 0.005). This appeared to be
mainly due to the USA stratum. The heterogeneity was
no longer significant after removal of that stratum (P-
het = 0.42) and the HR estimate for the association with
breast cancer risk increased to 1.20 (95% CI: 1.09 to
1.32, P-trend = 1 × 10-4). There was no heterogeneity
for any of the other SNPs (P-het > 0.12 for all, Addi-
tional file 1 Supplementary Figure 2). The HR estimates
Table 4 Competing risk analysis*. (Continued)
per allele 1.03 0.91 to 1.10 0.35 0.91 0.80 to 1.03 0.13
BRCA2 CC 2,106 (73.5) 2,716 (71.9) 333 (73.8) 1 1
CT 693 (24.2) 981 (26.0) 108 (24.0) 1.05 0.95 to 1.16 0.95 0.74 to 1.21
TT 66 (2.3) 83 (2.2) 10 (2.2) 0.96 0.71 to 1.28 0.87 0.46 to 1.63
2-df test 0.62 0.84
per allele 1.03 0.94 to 1.12 0.56 0.94 0.77 to 1.15 0.56
12q24 - rs1292011
BRCA1 AA 997 (34.1) 1,321 (35.4) 305 (34.9) 1 1
AG 1,406 (48.2) 1,765 (47.3) 429 (49.1) 1.00 0.90 to 1.10 1.11 0.93 to 1.31
GG 517 (17.7) 645 (17.3) 140 (16.0) 1.01 0.89 to 1.15 0.98 0.78 to 1.24
2-df test 0.97 0.39
per allele 1.00 0.94 to 1.07 0.91 1.01 0.91 to 1.13 0.82
BRCA2 AA 715 (35.0) 907 (35.9) 110 (36.5) 1 1
AG 961 (47.0) 1222 (48.4) 137 (45.5) 1.02 0.90 to 1.15 0.94 0.71 to 1.25
GG 370 (18.1) 396 (15.7) 54 (17.9) 0.83 0.70 to 0.97 0.89 0.61 to 1.28
2-df test 0.03 0.80
per allele 0.93 0.86 to 1.00 0.07 0.94 0.78 to 1.13 0.51
PTHLH - rs10771399
BRCA1 AA 3,810 (79.8) 5,179 (81.9) 1,145 (78.4) 1 1
AG 909 (19.0) 1078 (17.1) 289 (19.8) 0.89 0.81 to 0.97 1.09 0.93 to 1.26
GG 56 (1.2) 65 (1.0) 27 (1.9) 0.86 0.63 to 1.16 1.67 1.05 to 2.64
2-df test 0.02 0.06
per allele 0.90 0.83 to 0.97 6.4 × 10-3 1.14 1.00 to 1.30 0.06
BRCA2 AA 2,289 (79.7) 3,076 (81.2) 369 (81.5) 1 1
AG 545 (19.0) 678 (17.9) 76 (16.8) 0.94 0.84 to 1.06 0.88 0.67 to 1.16
GG 37 (1.3) 34 (0.9) 8 (1.8) 0.79 0.49 to 1.26 1.48 0.63 to 3.46
2-df test 0.38 0.43
per allele 0.93 0.84 to 1.04 0.19 0.96 0.75 to 1.23 0.75
9q31.2 - rs865686
BRCA1 TT 1,935 (40.5) 2,621 (41.5) 605 (41.3) 1 1
TG 2,206 (46.2) 2,825 (44.7) 690 (47.1) 0.94 0.88 to 1.01 0.99 0.87 to 1.12
GG 633 (13.3) 877 (13.9) 169 (11.5) 1.03 0.93 to 1.15 0.85 0.70 to 1.03
2-df test 0.12 0.23
per allele 1.00 0.95 to 1.05 0.88 0.94 0.86 to 1.03 0.17
BRCA2 TT 1,103 (38.4) 1,576 (41.6) 179 (39.6) 1 1
TG 1400 (48.8) 1712 (45.2) 215 (47.6) 0.85 0.77 to 0.94 0.91 0.73 to 1.14
GG 367 (12.8) 501 (13.2) 58 (12.8) 0.97 0.84 to 1.12 0.98 0.71 to 1.35
2-df test 4.6 × 10-3 0.70
per allele 0.94 0.88 to 1.01 0.10 0.97 0.83 to 1.13 0.67
Associations with breast and ovarian cancer risk for BRCA1 and BRCA2 carriers.
*Censoring process described in the methods
HR, hazard ratio
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for the four associated SNPs were similar when long-
term survivors were excluded from the analysis (Table
3). Consistent with the results of the main analysis,
rs10995190 in ZNF365 and rs1011970 near CDKN2A/
CDKN2B provided marginal evidence of association
using the trend-test statistic (P-trend = 0.05 for both)
and SNPs rs865686 was associated with breast cancer
risk under the genotype specific model (2df-P = 0.03).
SNP rs1292011 was not associated with breast cancer
risk in this analysis. A somewhat smaller HR estimate
was obtained for the PTHLH SNP rs10771399 compared
to the main analysis (per-allele HR = 0.89, 95% CI: 0.78
to 1.00, P-trend = 0.06). The attenuation of the associa-
tion in the overall analysis could have occurred if the
SNP is also associated with prognosis. However, the dif-
ference in the HRs was small. The results for the
remaining SNPs were similar and non-significant. None
of SNPs were associated with ovarian cancer risk for
BRCA2 mutation carriers (Table 4).
Associations by tumour ER-status
Table 5 summarises the associations of the eight SNPs
with breast cancer ER status in BRCA1 and BRCA2
mutation carriers. Only the PTHLH SNP rs10771399 was
associated with ER-negative breast cancer for BRCA1
mutation carriers (ER-negative HR = 0.81, 95% CI: 0.74
to 0.90, P-trend = 3.8 × 10-5). There was also marginal
evidence that SNP rs704010 near ZMIZ1 was associated
with ER-positive breast cancer for BRCA1 mutation car-
riers (ER-positive HR = 1.12, 95% CI: 1.00 to 1.26, P-
trend = 0.046). However, the associations between ER-
negative and ER-positive breast cancer among BRCA1
mutation carriers were only significantly different for
SNP rs1292011 at 12q24 (P-heterogeneity = 0.045).
Despite the small number of BRCA2 ER-negative
breast cancers, there was a suggestion that the minor
allele of the PTHLH SNP rs10771399 is protective for
ER-negative breast cancer for BRCA2 mutation carriers
(HR for ER-negative = 0.78, 95% CI: 0.62 to 1.00, P-
Table 5 Associations with estrogen receptor-positive and estrogen receptor-negative breast cancer risk for BRCA1 and
BRCA2 carriers.
ER-positive ER-negative
Unaffected
N
ER-positive N ER-negative N ER status unknown N HR 95% CI P-
value
HR 95% CI P-value P-dif
CDK2NA/B -
rs1011970
BRCA1 4,893 559 1,888 2,841 0.95 0.81 to 1.12 0.56 1.03 0.95 to 1.11 0.47 0.41
BRCA2 2,928 1,372 424 1,649 1.10 1.00 to 1.22 0.05 1.15 0.96 to 1.37 0.12 0.70
ZNF365 -
rs10995190
BRCA1 4,895 559 1,887 2,843 0.88 0.74 to 1.04 0.14 1.01 0.94 to 1.10 0.75 0.16
BRCA2 2,927 1,370 406 1,648 0.89 0.80 to 1.00 0.043 0.87 0.71 to 1.07 0.19 0.84
ZMIZ1 - rs704010
BRCA1 4,842 548 1,846 2,811 1.12 1.00 to 1.26 0.046 1.00 0.94 to 1.06 0.91 0.08
BRCA2 2,887 1,347 401 1,636 1.01 0.93 to 1.09 0.91 1.00 0.87 to 1.14 0.95 0.91
10p15 -
rs2380205
BRCA1 4,465 540 1,812 2,513 0.90 0.80 to 1.01 0.08 1.02 0.96 to 1.09 0.46 0.06
BRCA2 2,701 1,341 396 1,543 1.02 0.95 to 1.10 0.60 0.94 0.82 to 1.08 0.39 0.31
11q13 - rs614367
BRCA1 4,879 557 1,886 2,832 1.09 0.93 to 1.29 0.30 1.04 0.96 to 1.12 0.40 0.59
BRCA2 2,921 1,365 405 1,639 1.06 0.96 to 1.17 0.26 0.84 0.69 to 1.04 0.10 0.05
12q24 -
rs1292011
BRCA1 3,429 308 1,043 2,031 0.87 0.74 to 1.02 0.09 1.05 0.98 to 1.13 0.12 0.046
BRCA2 2,065 813 239 1,170 0.95 0.86 to 1.04 0.28 0.98 0.82 to 1.16 0.78 0.79
PTHLH -
rs10771399
BRCA1 4,889 557 1,887 2,842 0.94 0.78 to 1.13 0.52 0.81 0.74 to 0.90 3.8 × 10-5 0.20
BRCA2 2,926 1,366 406 1,648 0.97 0.86 to 1.10 0.68 0.78 0.62 to 1.00 0.049 0.12
9q31.2 - rs865686
BRCA1 4,892 559 1,888 2,836 0.92 0.81 to 1.03 0.15 1.01 0.95 to 1.08 0.68 0.16
BRCA2 2,924 1,370 405 1,645 0.91 0.84 to 0.99 0.028 1.07 0.92 to 1.25 0.40 0.08
ER, estrogen receptor; HR, hazard ratio
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trend = 0.049), but there was no association with ER-
positive breast cancer. There was evidence that SNPs
rs10995190 near ZNF365, rs865686 at 9q31.2 and
rs1011970 near CDKN2A/B are associated with ER-posi-
tive breast cancer for BRCA2 mutation carriers (P-trend
= 0.043, 0.028 and 0.05 respectively). However, the HR
estimates were not significantly different from those for
ER-negative breast cancer.
Discussion
We have investigated eight novel breast cancer suscept-
ibility loci identified through breast cancer GWAS
[15-17] for their associations with breast cancer risk for
BRCA1 and BRCA2 mutation carriers using data from
the CIMBA. The estimated per-allele ORs associated
with the minor allele of each SNP from the population-
based studies varied from 0.85 to 1.15, and only four of
the eight SNPs had ORs of less than 0.90 or greater
than 1.10 (rs10995190, rs614367, rs865686 and
rs10771399) [15-17]. For BRCA1 mutation carriers, only
SNP rs10771399 at 12p11 was associated with the over-
all risk of breast cancer, whereas SNPs rs10995190 at
10q21, rs1011970 at 9p21, rs865686 at 9q31.2 and
rs1292011 at 12q24 were associated with breast cancer
risk for BRCA2 mutation carriers. The magnitude of the
estimated HRs for all these SNPs were consistent with
the OR estimates for the risk of breast cancer in the
general population. The power to detect associations
with SNPs conferring relative risks in the range of 0.90
to 1.10 was limited by our sample size, particularly
among BRCA2 mutation carriers [29].
Based on the HR estimates and associated 95% confi-
dence intervals, given our sample size of BRCA1 muta-
tion carriers, it is unlikely that the relative risks for
overall BRCA1 breast cancer risk are of similar magni-
tude to those estimated in the general population for
SNPs rs10995190 at 10q21 (estimated odds ratio (OR)
from the replication stage of the GWAS = 0.76),
rs2380205 at 10p15 (OR = 0.94), rs614367 at 11q13 (OR
= 1.15), rs1292011 at 12q24 (OR = 0.92) and rs865686
at 9q31.2 (OR = 0.89), since the 95% confidence inter-
vals for the HRs do not include the estimated OR from
the population-based studies. Similarly, the HRs for
BRCA2 breast cancer risk exclude the ORs from the
general population for SNPs rs2380205 at 10p15 and
rs614367 at 11q13. Taken together, these findings sug-
gest that SNPs rs2380205 at 10p15 and rs614367 at
11q13 do not modify breast cancer risk in either BRCA1
or BRCA2 mutation carriers. A replication study by
BCAC, involving close to 50,000 breast cancer cases and
50,000 controls, found only weak evidence for associa-
tion of rs2380205 at 10p15 with breast cancer risk in
the general population [Lambrechts and Easton personal
communication, manuscript submitted] suggesting that
the original finding (OR = 0.94, P = 5 × 10-7 [15]) may
have been a false positive. If this were true, the absence
of an association in carriers would be expected. The
lack of evidence for an association with the 11q13 SNP
rs614367 with BRCA1 and BRCA2 breast cancer risk is
more surprising since the association in the general
population is relatively strong and consistently replicated
(OR 1.21, 95% CI 1.17 to 1.25 in the recent BCAC ana-
lysis [Lambrechts and Easton personal communication,
manuscript submitted]). The association in the general
population appears to be restricted to ER-positive dis-
ease, which would explain the lack of association for
BRCA1 carriers but not BRCA2 carriers. This is perhaps
the clearest evidence so far of a departure from a multi-
plicative interaction between a common susceptibility
locus and a BRCA2 mutation on the risk of developing
breast cancer. The lack of an association in BRCA1 car-
riers for rs1292011 and rs865686 is also consistent with
the observation that these associations are stronger for
ER-positive disease in the general population [16]. The
absence of an association for ZNF365 rs10995190 in
BRCA1 carriers is more surprising since this association
appears to be unrelated to ER status in the general
population [Lambrechts and Easton personal communi-
cation, manuscript submitted] [30].
Of the eight SNPs investigated, the strongest associa-
tion was found between SNP rs10771399 at 12p11 and
breast cancer risk for BRCA1 mutation carriers. Other
loci previously found to be associated with BRCA1
breast cancer risk include the 19p13 and 6q25.1 loci
[6,9], TOX3 and CASP8 [3,5,7]. Analysis by tumour ER-
status revealed that rs10771399 at 12p11 has a stronger
association with ER-negative than ER-positive breast
cancer for both BRCA1 and BRCA2 mutation carriers.
The ER-specific HRs were similar for both genes, sug-
gesting that this SNP is primarily associated with ER-
negative breast cancer, although results from the general
population suggested similar ORs for ER-positive and
ER-negative breast cancer (0.87 for ER-positive disease,
0.85 for ER-negative disease [16]). Interestingly, the
association among BRCA1 mutation carriers was
restricted to those carrying mutations proven or pre-
dicted to lead to absence of protein expression (Class 1)
with no evidence for an association in carriers of
BRCA1 mutations likely to generate stable mutant pro-
teins (Class 2) (P-diff = 0.03). This observation suggests
that the modifying effect of SNP rs10771399 at 12p11
might be attenuated for tumours that retain residual
BRCA1 function or that retain the capacity to bind to
some of its partners. rs10771399 lies in a region at
12p11 that contains PTHLH (parathyroid hormone-like
hormone isoform 1, also known as PTHRP - parathyroid
hormone-related protein) and CCDC91. PTHLH is a
plausible candidate cancer susceptibility gene. It encodes
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a protein that regulates endochondral bone development
and epithelial-mesenchymal interactions during the for-
mation of the mammary glands. The receptor of this
hormone, PTHR1, is responsible for most cases of
humoral hypercalcemia of malignancy [31]. It is pro-
duced by various types of carcinomas [32], and is an
important factor in the development of bone metastasis
[33].
We found that SNP rs10995190 ZNF365 is associated
with BRCA2 breast cancer risk. A different SNP
(rs16917302) in ZNF365, which is only weakly corre-
lated with rs10995190 (pairwise r2 is approximately 0.10
in the present sample) was previously identified via a
GWAS of breast cancer in BRCA2 mutation carriers
[10]. These results suggest that there could be a causal
associated variant correlated with both rs10995190 and
rs16917302, or alternatively more than one causal dis-
ease variant in this locus. SNP rs10995190 has also
recently been found to be associated with mammo-
graphic density in the general population [34]. Previous
studies found that mammographic density modifies
breast cancer risk for BRCA2 mutation carriers [35],
raising the possibility that this locus modifies breast
cancer risk for BRCA2 mutation carriers through its
influence on mammographic density. However, mam-
mographic density has also been shown to modify the
breast cancer risk for BRCA1 carriers, which also makes
the absence of association for rs10995190 in BRCA1 car-
riers somewhat surprising. Mammographic density data
are not available in the CIMBA sample to test this
hypothesis explicitly.
There was no evidence of association with ovarian
cancer risk for BRCA1 or BRCA2 mutation carriers for
any of the SNPs, with the exception of some weak evi-
dence for SNPs rs10771399 and rs614367 for BRCA1
carriers. This is not surprising, since all SNPs were
selected on the basis of prior evidence of association
with breast cancer risk in the general population and
none of these SNPs have so far been found to be asso-
ciated with ovarian cancer in general population
through the ongoing GWAS [36-38].
Conclusions
The per-allele HRs estimated for each of the associated
loci in the present report are modest, and in isolation
would have only a small impact on the absolute risks of
developing breast cancer. However, we have shown pre-
viously that modifier SNPs in combination can result in
large differences in the absolute risk of developing
breast cancer for carriers at the extreme percentiles of
the combined SNP distribution [5,39]. Furthermore, the
causal variants underlying these loci may confer larger
relative risks. Considering all reported modifying loci by
the CIMBA consortium, there are now six loci in total
that are associated with breast cancer risk for BRCA1
mutation carriers (19p13, 6q25.1, 12p11, TOX3, 2q35
and CASP8) and 13 loci which are known to be asso-
ciated with BRCA2 breast cancer risk (FGFR2, TOX3,
MAP3K1, LSP1, 2q35, SLC4A7, 5p12, 1p11.2, ZNF365,
CDKN2A/B, 9q31.2, 12q24 and RAD51). Ongoing
GWAS in BRCA1 and BRCA2 mutation carriers and in
the general population are likely to identify further
modifier loci and taken together, they may lead to more
accurate risk predictions in mutation carriers with
implications for clinical management, and to a better
understanding of the biology of tumour development in
mutation carriers.
Additional material
Additional file 1: Supplementary tables and figures. Table S1 List of
local ethics committees that granted approval for the access and use of
the data in current study. Supplementary figure 1 Forest plot of the
country-specific per-allele HR estimates for breast cancer for BRCA1
mutation carriers. Supplementary figure 2 Forest plot of the country-
specific per-allele HR estimates for breast cancer for BRCA2 mutation
carriers.
Abbreviations
BCAC: Breast Cancer Association Consortium; CIMBA: Consortium of
Investigators of Modifiers of BRCA1/2; ER: estrogen receptor; GWAS: genome-
wide association studies; HR: hazard ratio; HWE: Hardy-Weinberg equilibrium;
NMD: nonsense-mediated mRNA decay; OR: odds ratio; SNPs: single-
nucleotide polymorphism.
Acknowledgements
This work was supported by Cancer Research UK grants C12292/A11174 and
C1287/A10118. The research leading to these results has received funding
from the European Community’s Seventh Framework Programme under
grant agreement n° 223175 (HEALTH-F2-2009-223175), from the Canadian
Institutes of Health Research for the “CIHR Team in Familial Risks of Breast
Cancer” program and by the Canadian Breast Cancer Research Alliance-grant
#019511. This research was also supported by NIH grant CA128978, an NCI
Specialized Program of Research Excellence (SPORE) in Breast Cancer
(CA116201), a U.S. Department of Defence Ovarian Cancer Idea award
(W81XWH-10-1-0341) and grants from the Breast Cancer Research
Foundation and the Komen Foundation for the Cure. ACA is a CR-UK Senior
Cancer Research Fellow, DFE is CR-UK Principal Research Fellow, GCT is a
NHMRC Senior Principal Research Fellow, J.S. is Chairholder of the Canada
Research Chair in Oncogenetics.
Study specific
Baltic Familial Breast and Ovarian Cancer Consortium
We acknowledge the Genome Database of Latvian Population, Latvian
Biomedical
Research and Study Centre and Ramunas Janavicius (Vilnius University
Hospital Santariskiu Clinics, Lithuania) for data and DNA samples for BFBOCC.
The work was supported in part by a grant from the European Social Fund
Nr.2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016.
BMBSA was supported by grants from the Cancer Association of South Africa
(CANSA) to Elizabeth J. van Rensburg.
Breast Cancer Family Registry (BCFR)
This work was supported by the National Cancer Institute, National Institutes
of Health under RFA-CA-06-503 and through cooperative agreements with
members of the Breast Cancer Family Registry (BCFR) and Principal
Investigators, including Cancer Care Ontario (U01 CA69467), Columbia
University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631),
Huntsman Cancer Institute (U01 CA69446), Cancer Prevention Institute of
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 13 of 18
California (formerly the Northern California Cancer Center) (U01 CA69417),
University of Melbourne (U01 CA69638), and Research Triangle Institute
Informatics Support Center (RFP No. N02PC45022-46). Samples from the
FCCC, HCI and CPIC were processed and distributed by the Coriell Institute
for Medical Research. The content of this manuscript does not necessarily
reflect the views or policies of the National Cancer Institute or any of the
collaborating centres in the BCFR, nor does mention of trade names,
commercial products or organizations imply endorsement by the US
Government or the BCFR.
CNIO
The research leading to these results has been partially funded by Mutua
Madrileña Foundation, “Red de Investigación en Cáncer RD06/0020/1160”
and Spanish Ministry of Science and Innovation (FIS PI08 1120 and SAF2010-
20493).
Copenhagen Breast Cancer Study (CBCS)
We would like to thank Bent Ejlertsen for clinical data and acknowledge the
NEYE foundation for financial support.
Deutsches Krebsforschungszentrum (DKFZ) study
The DKFZ study was supported by the DKFZ.
Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE)
Douglas F. Easton is the PI of the study. EMBRACE Collaborating Centres are:
Coordinating Centre, Cambridge: Susan Peock, Debra Frost, Steve D. Ellis,
Elena Fineberg, Radka Platte, Clare Oliver. North of Scotland Regional
Genetics Service, Aberdeen: Zosia Miedzybrodzka, Helen Gregory. Northern
Ireland Regional Genetics Service, Belfast: Patrick Morrison, Lisa Jeffers. West
Midlands Regional Clinical Genetics Service, Birmingham: Trevor Cole, Kai-ren
Ong, Jonathan Hoffman. South West Regional Genetics Service, Bristol: Alan
Donaldson, Margaret James. East Anglian Regional Genetics Service,
Cambridge: Joan Paterson, Sarah Downing, Amy Taylor. Medical Genetics
Services for Wales, Cardiff: Alexandra Murray, Mark T. Rogers, Emma McCann.
St James’s Hospital, Dublin and National Centre for Medical Genetics, Dublin:
M. John Kennedy, David Barton. South East of Scotland Regional Genetics
Service, Edinburgh: Mary Porteous, Sarah Drummond. Peninsula Clinical
Genetics Service, Exeter: Carole Brewer, Emma Kivuva, Anne Searle, Selina
Goodman, Kathryn Hill. West of Scotland Regional Genetics Service, Glasgow:
Rosemarie Davidson, Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark
Longmuir, Catherine Watt, Sarah Gibson, Eshika Haque, Ed Tobias, Alexis
Duncan. South East Thames Regional Genetics Service, Guy’s Hospital
London: Louise Izatt, Chris Jacobs, Caroline Langman. North West Thames
Regional Genetics Service, Harrow: Huw Dorkins. Leicestershire Clinical
Genetics Service, Leicester: Julian Barwell. Yorkshire Regional Genetics
Service, Leeds: Julian Adlard, Gemma Serra-Feliu. Cheshire & Merseyside
Clinical Genetics Service, Liverpool: Ian Ellis, Catherine Houghton. Manchester
Regional Genetics Service, Manchester: D Gareth Evans, Fiona Lalloo, Jane
Taylor. North East Thames Regional Genetics Service, NE Thames, London:
Lucy Side, Alison Male, Cheryl Berlin. Nottingham Centre for Medical
Genetics, Nottingham: Jacqueline Eason, Rebecca Collier. Northern Clinical
Genetics Service, Newcastle: Fiona Douglas, Oonagh Claber, Irene Jobson.
Oxford Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod,
Dorothy Halliday, Sarah Durell, Barbara Stayner. The Institute of Cancer
Research and Royal Marsden NHS Foundation Trust: Ros Eeles, Susan
Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Elizabeth
Page, Audrey Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Anita
Mitra, Lisa Robertson. North Trent Clinical Genetics Service, Sheffield: Jackie
Cook, Oliver Quarrell, Cathryn Bardsley. South West Thames Regional
Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie
Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard. Wessex Clinical
Genetics Service, Princess Anne Hospital, Southampton: Diana Eccles, Anneke
Lucassen, Gillian Crawford, Donna McBride, Sarah Smalley. EMBRACE is
supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990.
D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the
Biomedical Research Centre, Manchester. The Investigators at The Institute of
Cancer Research and The Royal Marsden NHS Foundation Trust are
supported by an NIHR grant to the Biomedical Research Centre at The
Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
Ros Eeles is supported by Cancer Research UK Grant C5047/A8385.
GEORGETOWN
CI received support from the Familial Cancer Registry and the Tissue Culture
Shared Registry at Georgetown University (NIH/NCI grant P30-CA051008), the
Cancer Genetics Network (HHSN261200744000C), and Swing Fore the Cure.
Gynecologic Oncology Group (GOG)
This study was supported by National Cancer Institute grants to the
Gynecologic Oncology Group (GOG) Administrative Office and the GOG
Tissue Bank (CA 27469), and to the GOG Statistical and Data Center (CA
37517 and CA 101165). We thank the investigators of the Australia New
Zealand Gynaecological Oncology Group (ANZGOG). GOG’s participation was
sponsored by GOG’s Cancer Prevention and Control Committee, and
supported through funding provided by both intramural (Clinical Genetics
Branch, DCEG) and extramural (Community Oncology and Prevention Trials
Program - COPTRG) NCI programs.
Hospital Clinico San Carlos (HCSC)
The HCSC study was partially supported by Instituto de Salud Carlos III;
RD06/0020/0021. We wish to thank Dr. Pedro Perez-Segura and Dr. Atocha
Romero for their contribution to this study.
The Hereditary Breast and Ovarian Cancer Research Group Netherlands
(HEBON)
HEBON Collaborating Centres: Coordinating center: Netherlands Cancer
Institute, Amsterdam, NL: F.B.L. Hogervorst, S. Verhoef, M. Verheus, L.J. van ‘t
Veer, F.E. van Leeuwen, M.A. Rookus; Erasmus Medical Center, Rotterdam, NL:
M. Collée, A.M.W. van den Ouweland, A. Jager, M.J. Hooning, M.M.A. Tilanus-
Linthorst, C. Seynaeve; Leiden University Medical Center, NL, Leiden: C.J. van
Asperen, J.T. Wijnen, M.P. Vreeswijk, R.A. Tollenaar, P. Devilee; Radboud
University Nijmegen Medical Center, Nijmegen, NL: M.J. Ligtenberg, N.
Hoogerbrugge; University Medical Center Utrecht, Utrecht, NL: M.G. Ausems,
R.B. van der Luijt; Amsterdam Medical Center, NL: C.M. Aalfs, T.A. van Os; VU
University Medical Center, Amsterdam, NL: J.J.P. Gille, Q. Waisfisz, H.E.J.
Meijers-Heijboer; University Hospital Maastricht, Maastricht, NL: E.B. Gomez-
Garcia, C.E. van Roozendaal, Marinus J. Blok, B. Caanen; University Medical
Center Groningen University, NL: J.C. Oosterwijk, A.H. van der Hout, M.J.
Mourits; The Netherlands Foundation for the detection of hereditary
tumours, Leiden, NL: H.F. Vasen. The HEBON study is supported by the
Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756 and
the ZonMW grant 91109024.
Helsinki Breast Cancer Study (HEBCS)
HEBCS acknowledge Drs. Kristiina Aittomäki, Kirsimari Aaltonen and Carl
Blomqvist and Tuomas Heikkinen and research nurse Irja Erkkilä for their
help with the patient data and samples. The HEBCS study has been
financially supported by the Helsinki University Central Hospital Research
Fund, Academy of Finland (132473), the Finnish Cancer Society, and the
Sigrid Juselius Foundation.
ICO
Contract grant sponsor: Asociación Española Contra el Cáncer, Spanish
Health Research Fund; Carlos III Health Institute; Catalan Health Institute and
Autonomous Government of Catalonia. Contract grant numbers: ISCIIIRETIC
RD06/0020/1051, PI10/01422, PI10/31488 and 2009SGR290.
ILUH
The ILUH group was supported by the Icelandic Association “Walking for
Breast Cancer Research” and by the Landspitali University Hospital Research
Fund.
INHERIT
We would like to thank Stéphane Dubois, Dr Martine Dumont, Martine
Tranchant (Cancer Genomics Laboratory, CRCHUQ) for sample management
and skillful technical assistance, Sylvie Desjardins and Marc-André Rodrigue
(Plateforme de séquençage et de génotypage des génome du CRCHUL/
CHUQ) for iPLEX genotyping and Pascal Belleau for data quality control
analyses.
Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study
(IOVHBOCS)
This study was supported by Ministero dell’Istruzione, dell’Università e della
Ricerca (MIUR) and “Ministero della Salute” ("Progetto Tumouri Femminili and
grant numbers RFPS 2006-5-341353, ACC2/R6.9”)
kConFab
We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab
research nurses and staff, the heads and staff of the Family Cancer Clinics,
and the Clinical Follow Up Study (funded 2001-2009 by NHMRC and
currently by the National Breast Cancer Foundation and Cancer Australia
#628333) for their contributions to this resource, and the many families who
contribute to kConFab. kConFab is supported by grants from the National
Breast Cancer Foundation, the National Health and Medical Research Council
(NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New
South Wales, Victoria, Tasmania and South Australia, and the Cancer
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 14 of 18
Foundation of Western Australia. ABS is funded by an NHMRC Senior
Research Fellowship.
Memorial Sloan-Kettering Cancer Center (MSKCC)
We acknowledge the Starr Cancer Consortium, the Breast Cancer Research
Foundation, the Norman and Carol Stone Cancer Research Initiative, the Kate
and Robert Niehaus Clinical Cancer Research Initiative, the Lymphoma
Foundation, and the Sabin Family Research Initiative.
National Cancer Institute (NCI)
The research of Drs. Greene and Loud was supported by the Intramural
Research Program of the US National Cancer Institute at the National
Institutes of Health, and by support services contracts NO2-CP-11019-50 and
N02-CP-65504 with Westat, Inc, Rockville, MD.
N.N. Petrov Institute of Oncology (NNPIO)
This work has been supported by the Russian Federation for Basic Research
(grants 10-04-92601, 10-04-92110, 11-04-00227) the Federal Agency for
Science and Innovations (contract 16.512.11.2237) and through a Royal
Society International Joint grant (JP090615).
The Hong Kong Hereditary Breast Cancer Family Registry thank Dr. Ellen Li
Charitable Foundation for their support
Hungarian Breast and Ovarian Cancer Study (HUNBOCS)
The study was supported by Norwegian EEA Financial Mechanism (HU0115/
NA/2008-3/ÖP-9) and by Hungarian Research Grant KTIA-OTKA (CK-80745).
Ohio State University Clinical Cancer Genetics (OSU-CCG)
Leigha Senter and Kevin Sweet were instrumental in accrual of study
participants, ascertainment of medical records and database management.
We thank the Human Genetics Sample Bank for preparation of samples. This
study was supported by the Ohio State University Comprehensive Cancer
Center.
Ontario Cancer Genetics Network Study (OCGN)
This work was supported by Cancer Care Ontario, the “CIHR Team in Familial
Risks of Breast Cancer” program, and the US National Cancer Institute,
National Institutes of Health under RFA # CA- 06-503 and through
cooperative agreements with members of the Breast Cancer Family Registry
(BCFR) and Principal Investigators. The content of this manuscript does not
necessarily reflect the views or policies of the National Cancer Institute or
any of the collaborating centres in the BCFR, nor does mention of trade
names, commercial products, or organizations imply endorsement by the US
Government or the BCFR. We wish to thank Teresa Selander, Nayana
Weerasooriya and members of the Ontario Cancer Genetics Network for
their contributions to the study.
Beckman Research Institute of City of Hope (BRICOH)
The study was supported by the National Institutes of Health (R01 CA74415
to SLN)) and the Morris and Horowitz Families Endowment.
SWE-BRCA
SWE-BRCA collaborators: Per Karlsson, Margareta Nordling, Annika Bergman
and Zakaria Einbeigi, Gothenburg, Sahlgrenska University Hospital; Marie
Stenmark-Askmalm and Sigrun Liedgren, Linköping University Hospital; Åke
Borg, Niklas Loman, Håkan Olsson, Maria Soller, Helena Jernström, Katja
Harbst and Karin Henriksson, Lund University Hospital; Annika Lindblom,
Brita Arver, Anna von Wachenfeldt, Annelie Liljegren, Gisela Barbany-Bustinza
and Johanna Rantala, Stockholm, Karolinska University Hospital; Beatrice
Melin, Henrik Grönberg, Eva-Lena Stattin and Monica Emanuelsson, Umeå
University Hospital; Hans Ehrencrona, Richard Rosenquist and Niklas Dahl,
Uppsala University Hospital.
U.K. and Gilda Radner Familial Ovarian Cancer Registry (UKGRFOCR)
UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We
thank Paul Pharoah, Susan Ramus, Carole Pye, Patricia Harrington and Eva
Wozniak for their contributions towards the UKFOCR. We would like to
acknowledge the Roswell Park Alliance Foundation for their continued
support of the Gilda Radner Ovarian Family Cancer Registry. GRFOCR would
like to acknowledge Kirsten Moysich and Lara Sucheston (Department of
Cancer Prevention and Control).
University of Kansas Medical Center (KUMC)
We thank Ms. JoEllen Weaver for her help collecting patient data and
samples. AKG was funded by U01CA69631, 5U01CA113916, and the Eileen
Stein Jacoby Fund while at FCCC. The author acknowledges support from
The University of Kansas Cancer Center and the Kansas Bioscience Authority
Eminent Scholar Program. AKG is the Chancellors Distinguished Chair in
Biomedical Sciences endowed Professor.
University of Pennsylvania (UPENN)
This research was supported by the Breast Cancer Research Foundation (to
KLN) and the Komen Foundation for the Cure (to SMD).
Women’s Cancer Program - Cedars-Sinai Medical Center (WCRI)
This work is supported by funding from the American Cancer Society
Clinical Research Professorship (SIOP-06-258-COUN).
Author details
1Centre for Cancer Genetic Epidemiology, Department of Public Health and
Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK.
2Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec, 2705
Laurier Boulevard, T3-57, Quebec City, QC Canada. 3Genetics and Population
Health Division, Queensland Institute of Medical Research, 300 Herston Rd,
Herston, Brisbane, QLD 4006, Australia. 4Unité Mixte de Génétique
Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon/
Centre Léon Bérard, 28 rue Laënnec, Lyon 69373, France and INSERM U1052,
CNRS UMR5286, Université Lyon 1, Cancer Research Center of Lyon, 28 rue
Laënnec, Lyon 69373, France. 5Section of Genetic Oncology, Dept. of Laboratory
Medicine, University and University Hospital of Pisa, Via Roma 57, 56125 Pisa, Italy.
6Department of Oncology, Lund University Hospital, Lund, Sweden. 7Department
of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
8Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
9Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University,
Uppsala, Sweden. 10Department of Oncology, Sahlgrenska University Hospital,
Gothenburg, Sweden. 11Abramson Cancer Center, Perelman School of Medicine
at the University of Pennsylvania, Philadelphia, PA, USA. 12Department of Genetics
and Pathology, Pomeranian Medical University, Szczecin, Poland. 13Department of
Genetics and Pathology, Pomeranian Medical University, Szczecin and
Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw,
Poland. 14Human Genetics Group, Human Cancer Genetics Programme, Spanish
National Cancer Research Centre, Madrid, Spain and Spanish Network on Rare
Diseases (CIBERER). 15Institute of Biology and Molecular Genetics. Universidad de
Valladolid (IBGM-UVA), Valladolid, Spain. 16Oncology unit. Hospital clinico
Universitario “Lozano Blesa”, Zaragoza, Spain. 17Human Genetics Group and
Genotyping Unit, Human Cancer Genetics Programme, Spanish National Cancer
Research Centre, Madrid, Spain and Spanish Network on Rare Diseases (CIBERER).
18Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum
(DKFZ), Heidelberg, Germany. 19Family Cancer Clinic, Netherlands Cancer Institute,
Amsterdam, The Netherlands. 20Department of Clinical Genetics, Academic Meical
Center, Amsterdam, The Netherlands. 21Department of Clinical Genetics,
Netherlands Cancer Institute, Amsterdam, The Netherlands. 22Department of
Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands. 23Department
of Clinical Genetics and GROM, School for Oncology and Developmental Biology,
MUMC, Maastricht, The Netherlands. 24Department of Clinical Genetics and
GROM, School for Oncology and Developmental Biology, MUMC, Maastricht, The
Netherlands. 25Department of Human Genetics, Radboud University Nijmegen
Medical Center, Nijmegen, The Netherlands. 26Department of Clinical Genetics,
Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The
Netherlands. 27Department of Clinical Genetics, Family Cancer Clinic, Erasmus
University Medical Center, Rotterdam, The Netherlands. 28Department of Medical
Genetics, University Medical Center Utrecht, PO Box 85090, 3508 AB Utrecht, The
Netherlands. 29Department of Genetics, University Medical Center, Groningen
University, Groningen, The Netherlands. 30Netherlands Cancer Institute,
Amsterdam, The Netherlands. 31Genetic Medicine, Manchester Academic Health
Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust,
Manchester, UK. 32Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust,
London, UK. 33Oncogenetics Team, The Institute of Cancer Research and Royal
Marsden NHS Foundation Trust, UK. 34Yorkshire Regional Genetics Service, Leeds,
UK. 35Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow, UK.
36West Midlands Regional Genetics Service, Birmingham Women’s Hospital
Healthcare NHS Trust, Edgbaston, Birmingham, UK. 37Sheffield Clinical Genetics
Service, Sheffield Children’s Hospital, Sheffield, UK. 38Department of Clinical
Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital,
Cambridge, UK. 39Institute of Genetic Medicine, Centre for Life, Newcastle Upon
Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK. 40Department of Clinical
Genetics, Royal Devon & Exeter Hospital, Exeter, UK. 41Medical Genetics Unit, St
George’s, University of London, UK. 42Northern Ireland Regional Genetics Centre,
Belfast Health and Social Care Trust, and Department of Medical Genetics,
Queens University Belfast, Belfast UK. 43Oxford Regional Genetics Service, Churchill
Hospital, Oxford, UK. 44All Wales Medical Genetics Services, University Hospital of
Wales, Cardiff, UK. 45Clinical Genetics Department, St Michael’s Hospital, Bristol, UK.
46North West Thames Regional Genetics Service, Kennedy-Galton Centre, Harrow,
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 15 of 18
UK. 47Department of Pathology and Laboratory Medicine, University of Kansas
Medical Center, Kansas City, KS, USA. 48Clinical Molecular Genetics Laboratory, Fox
Chase Cancer Center, Philadelphia, PA, USA. 49Service de Génétique Oncologique,
Institut Curie, Paris, France, Unité INSERM U830, Institut Curie, Paris, France,
Université Paris Descartes, Faculté de Médecine, Paris, France. 50Service de
Génétique Oncologique, Institut Curie, Paris, France and Université Paris
Descartes, Faculté de Pharmacie, Paris, France. 51Service de Génétique
Oncologique, Institut Curie, 26 rue d’Ulm, Paris, France. 52Service de Génétique
Oncologique, Institut Curie, Paris, France. 53INSERM U1052, CNRS UMR5286,
Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
54Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices
Civils de Lyon / Centre Léon Bérard, Lyon, France. 55Service de Génétique, Institut
de Cancérologie Gustave Roussy, Villejuif, France and INSERM U946, Fondation
Jean Dausset, Paris, France. 56Consultation de Génétique, Département de
Médecine, Institut de Cancérologie Gustave Roussy, Villejuif, France.
57Département Oncologie génétique, Prévention et Dépistage, INSERM CIC-
P9502, Institut Paoli-Calmettes/Université d’Aix-Marseille II, Marseille, France.
58Centre Antoine Lacassagne, Nice, France. 59Service de Génétique Clinique
Chromosomique et Moléculaire, Centre Hospitalier Universitaire de St Etienne, St
Etienne, France. 60Laboratoire de Génétique Chromosomique, Hôtel Dieu Centre
Hospitalier, BP 1125 Chambéry, France. 61Service de Génétique, Centre Hospitalier
Universitaire Bretonneau, Tours, France. 62Cancer Genetics Network “Groupe
Génétique et Cancer”, Fédération Nationale des Centres de Lutte Contre le
Cancer, France. 63Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City,
UT 84112, USA. 64Division of Population Science, Fox Chase Cancer Center, 333
Cottman Avenue, Philadelphia, PA 19111, USA. 65Department of Cancer Biology,
Dana-Farber Cancer Institute, and Department of Surgery, Harvard Medical
School, 27 Drydock Avenue, Boston, MA 02210, USA. 66Department of
Epidemiology, Columbia University, New York, NY, USA. 67Centre for Molecular,
Environmental, Genetic and Analytic (MEGA) Epidemiology, Melbourne School of
Population Health, Level 1, 723 Swanston Street, The University of Melbourne,
Victoria 3010, Australia. 68Department of Epidemiology, Cancer Prevention
Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538, USA.
69Genetic Epidemiology Laboratory, Department of Pathology, University of
Melbourne, Australia. 70Department of Dermatology, University of Utah School of
Medicine, 30 North 1900 East, SOM 4B454, Salt Lake City, UT 84132, USA. 71Dept
of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna,
Vienna, Austria. 72Center for Genomic Medicine, Rigshospitalet, Copenhagen
University Hospital, Copenhagen, Denmark. 73Department of Pathology,
Landspitali - University Hospital, Reykjavik Iceland and Faculty of Medicine,
University of Iceland, Reykjavik, Iceland. 74Epidemiology Research Program,
American Cancer Society, Atlanta, GA, USA. 75Department of Environmental
Medicine, NYU Cancer Institute, New York University School of Medicine, New
York, NY. 76Clinical Cancer Genetics Laboratory, Memorial Sloane Kettering Cancer
Center, New York, NY. 77Statistical and Data Center, Roswell Park Cancer Institute,
Buffalo, USA. 78Australia New Zealand (ANZGOG), Westmead Hospital, Sydney,
Australia. 79Ohio State University, Columbus Cancer Council, OH, USA. 80Evanston
CCOP - NorthShore University Health System; University of Chicago, USA.
81Southern Pines Women’s Health Center, P.C., University of North Carolina at
Chapel Hill, USA. 82Sarasota Memorial Healthcare, Tufts Medical Center, USA.
83Departments of Molecular Virology, Immunology & Medical Genetics and
Internal Medicine, Comprehensive Cancer Center, The Ohio State University,
Columbus, OH 43210, USA. 84Immunology and Molecular Oncology Unit, Istituto
Oncologico Veneto IOV - IRCCS, Padua, Italy. 85U.O.C. di Oncologia, ULSS5 Ovest
Vicentino, Italy. 86Laboratory of Molecular Oncology, N.N. Petrov Institute of
Oncology, St.-Petersburg, Russia. 87Lombardi Comprehensive Cancer Center,
Georgetown University, Washington DC, USA. 88Latvian Biomedical Research and
Study Centre, Latvia. 89Genetic Counselling Unit, Hereditary Cancer Program,
IDIBELL-Catalan Institute of Oncology. 90Molecular Diagnostic Unit, Hereditary
Cancer Program, IDIBELL-Catalan Institute of Oncology. 91Department of
Preventive Medicine, Keck School of Medicine, University of Southern California,
California, USA. 92Department of Gynecologic Oncology, Roswell Park Cancer
Institute, Buffalo, NY, USA. 93Women’s Cancer Program at the Samuel Oschin
Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles,
USA. 94Department of Molecular Genetics, National Institute of Oncology,
Budapest, Hungary. 95Cancer Research Initiatives Foundation, Sime Darby Medical
Centre, Malaysia and University Malaya Cancer Research Institute, University
Malaya Medical Centre, Malaysia. 96Jonsson Comprehensive Cancer Center at
UCLA, Los Angeles, CA, USA. 97UCSF Cancer Risk Program, University of California,
San Francisco; UCSF Departments of Medicine, Epidemiology, and Biostatistics,
USA. 98Cancer Genetics Laboratory, Department of Genetics, University of Pretoria,
South Africa. 99Oncogenetics Laboratory. Vall d’Hebron Institute of Oncology
(VHIO), Vall d’Hebron University Hospital. Barcelona Spain. 100The Hong Kong
Hereditary Breast Cancer Family Registry; The Universtiy of Hong Kong; Cancer
Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong. 101Centre of
Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics
and Centre for Integrated Oncology (CIO), University hospital of Cologne,
Germany. 102Institute for Medical Informatics, Statistics and Epidemiology,
University of Leipzig, Germany. 103Department of Gynaecology and Obstetrics,
Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich,
Germany. 104Department of Gynaecology and Obstetrics, Ludwig-Maximilian
University Munich, Germany. 105Department of Gynaecology and Obstetrics,
University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts
University Kiel, Germany. 106Institute of Human Genetics, University Hospital of
Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Germany.
107Department of Gynaecology and Obstetrics, University Hospital Düsseldorf,
Heinrich-Heine University Düsseldorf, Germany. 108Institute of Human Genetics,
University of Münster, Münster, Germany. 109Institute of Cell and Molecular
Pathology, Hannover Medical School, Hannover, Germany. 110Institute of Human
Genetics, Campus Virchov Klinikum, Charite Berlin, Germany. 111Department of
Gynaecology and Obstetrics, University Hospital Ulm, Germany. 112Centre of
Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of
Human Genetics, University Würzburg, Germany. 113Institute of Human Genetics,
Department of Human Genetics, University Hospital Heidelberg, Germany.
114Department of Gynaecology and Obstetrics, University Hospital Carl Gustav
Carus, Technical University Dresden, Germany. 115Institute of Human Genetics,
University Regensburg, Germany. 116Institute of Human Genetics, University
Hospital Frankfurt a.M., Germany. 1Molecular Oncology Laboratory, Hospital
Clinico San Carlos, Madrid, Spain. 117Molecular Oncology Laboratory, Hospital
Clinico San Carlos, Martin Lagos s/n, Madrid, Spain. 118Department of Obstetrics
and Gynecology, University of Helsinki and Helsinki University Central Hospital,
Biomedicum Helsinki, P.O. BOX 700, 00029 HUS, Helsinki, Finland. 119Faculty of
Medicine - Medicine and Medical Specialties, Université de Montréal. 1Hemato-
oncology service, Hôpital du Sacré-Coeur de Montréal, 5400 Gouin Blvd West
Montreal, Quebec, Canada. 120Peter MacCallum Cancer Center, Melbourne,
Australia. 121Department of Population Sciences, Beckman Research Institute of
City of Hope, Duarte, CA. USA. 122Department of Laboratory Medicine and
Pathology, Mayo Clinic, Rochester, MN, USA. 123Department of Medical Genetics,
Mayo Clinic, Rochester, MN, USA. 124Department of Health Sciences Research,
Mayo Clinic, Rochester, MN, USA. 125Unit of Molecular Bases of Genetic Risk and
Genetic Testing, Department of Preventive and Predicted Medicine, Fondazione
IRCCS Istituto Nazionale Tumori (INT), Milan, Italy and IFOM, Fondazione Istituto
FIRC di Oncologia Molecolare, Milan, Italy. 126Unit of Medical Genetics,
Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto
Nazionale Tumori (INT), Milan, Italy. 127Division of Cancer Prevention and Genetics,
Istituto Europeo di Oncologia (IEO), Milan Italy. 128Department of Experimental
Oncology, Istituto Europeo di Oncologia, Milan, Italy and Consortium for
Genomics Technology (Cogentech), Milan, Italy. 129Cancer Bioimmunotherapy
Unit, Centro di Riferimento Oncologico, IRCCS,. 1Aviano (PN), Italy. 130Medical
Genetics Unit, Department of Clinical Physiopathology, University of. 1Florence,
Firenze, Italy. 131Department of Molecular Medicine, “Sapienza” University of
Rome, Rome, Italy. 132Clinical Genetics Branch, DCEG, NCI; Room EPS 7032,
Rockville MD 20852 USA. 133Samuel Lunenfeld Research Institute, Mount Sinai
Hospital, Toronto, Ontario; Cancer Care Ontario, Departments of Molecular
Genetics and Laboratory Medicine and Pathobiology, University of Toronto,
Ontario, Canada. 134Samuel Lunenfeld Research Institute, Mount Sinai Hospital,
Toronto, Ontario, Department of Laboratory Medicine and Pathobiology,
University of Toronto, Ontario, Canada. 135Department of Laboratory Medicine
and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of
Laboratory Medicine, and the Keenan Research Centre of the Li Ka Shing
Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada. 136Ontario
Cancer Genetics Network: Cancer Care Ontario, Canada. 137Department of Clinical
Genetics, Odense University Hospital, Denmark. 138Department of Clincial
Genetics, Rigshospital and Copenhagen University, Denmark. 139Department of
Clinical Genetics, Skejby Hospital, Aarhus, Denma. 140Department of Clinical
Genetics, Vejle Hospital, Denmark. 141Department of Laboratory Medicine and
Pathology, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
142Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec, 2705
Laurier Boulevard, T3-57, Quebec City and Canada Research Chair in
Oncogenetics, Department of Molecular Medicine, Faculty of Medicine, Laval
University, Quebec, Canada.
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 16 of 18
Authors’ contributions
ACA, KBK and DFE wrote the manuscript. KBK performed the statistical
analysis. ACA supervised the statistical analysis and data management. ACA,
GCT and DFE developed the study design. LM and DB are the CIMBA
database managers. AL wrote computer programs for the analysis. SH and
OMS reviewed, recoded and classified the BRCA1 and BRCA2 mutations in
CIMBA. GCT initiated and coordinates CIMBA. PS, JB, XC and YCD performed
the genotyping. AJ, SLN, GCT and JS supervised the genotyping of samples.
MAC, NL, KH, AL, BA, RR, PK, KN, SD, TR, AJ, JL, KJ, KD, EZ, AO, MD, RA, JB,
UH, FBH, TAvO, SV, HEJMH, JW, EBGG, MJL, MK, JMC, MGEMA, JCO, SP, DF,
SDE, RP, EF, DGE, FL, CJ, RE, JA, RD, TC, JC, JP, FD, CB, SH, PJM, LW, MTR, AD,
HD, AKG, BB, DS, CH, BB, AdP, SM, AC, ML, BBdeP, OC, HS, MF, FP, SFF, IM,
SB, MD, AM, MBT, JLH, EMJ, MS, DG, CFS, AFR, MKT, DGK, TvOH, FCN, RBB,
MG, TK, VJ, ADC, KO, MP, JK, DC, JH, JB, JF, AET, MM, CO, EI, CI, LT, IB, CL, AT,
JDV, SAG, KO, JG, BYK, EO, SHT, PAG, MSB, CMD, EJvR, OD, AK, RKS, BW, CE,
AM, ND, NA, SH, DN, SPA, DG, RVM, HD, AG, CS, KK, BF, DS, TC, MdlH, HN,
TAM, BL, ABS, SLN, YCD, XW, ZF, VSP, NML, PR, MHG, JTL, ILA, HO, AMM, GG,
MT, AMG, UBJ, ABS, TAK, GCT and FJC acquired phenotypic data and DNA
samples or designed the centre-specific studies. All authors read and
approved the final manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 21 September 2011 Revised: 15 November 2011
Accepted: 20 February 2012 Published: 20 February 2012
References
1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL,
Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S,
Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J,
Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H,
Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, et al: Average
risks of breast and ovarian cancer associated with BRCA1 or BRCA2
mutations detected in case Series unselected for family history: a
combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
2. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC,
Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M,
Liang X, Hummer AJ, Sima C, Bernstein JL: Variation of breast cancer risk
among BRCA1/2 carriers. JAMA 2008, 299:194-201.
3. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA,
Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W,
Sutter C, Niederacher D, Deissler H, Caldes T, Kampjarvi K, Nevanlinna H,
Simard J, Beesley J, Chen X, Neuhausen SL, Rebbeck TR, Wagner T,
Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI,
et al: Common breast cancer-predisposition alleles are associated with
breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum
Genet 2008, 82:937-948.
4. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H,
Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X, Neuhausen SL,
Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B,
Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M,
Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, et al:
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for
BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009, 18:4442-4456.
5. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S,
Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C,
Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM,
Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A,
Allavena A, Dall’olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, et al:
Common breast cancer susceptibility alleles and the risk of breast
cancer for BRCA1 and BRCA2 mutation carriers: implications for risk
prediction. Cancer Res 2010, 70:9742-9754.
6. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S,
Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E,
Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Laura PA, Varesco L,
Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H,
Thomassen M, Gerdes AM, Kruse TA, Birk JU, Cruger DG, et al: Common
alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for
BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2011, 20:3304-3321.
7. Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S,
Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C,
McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L,
Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L,
Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, et al:
Association of the variants CASP8 D302H and CASP10 V410I with breast
and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer
Epidemiol Biomarkers Prev 2010, 19:2859-2868.
8. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J,
Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z,
Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A,
Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH,
Mai PL, Andrulis IL, Glendon G, Ozcelik H, et al: Genetic variation at 9p22.2
and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl
Cancer Inst 2010, 103:105-116.
9. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R,
Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M,
Barrowdale D, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG,
Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D,
Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, et al: A
locus on 19p13 modifies risk of breast cancer in BRCA1 mutation
carriers and is associated with hormone receptor-negative breast cancer
in the general population. Nat Genet 2010, 42:885-892.
10. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segre AV,
McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM,
Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M,
Frenay M, Gemo SC, Hogervorst FB, Rookus MA, Collee JM,
Hoogerbrugge N, van Roozendaal KE, Piedmonte M, Rubinstein W,
Nerenstone S, Van Le L, Blank SV, et al: Common genetic variants and
modification of penetrance of BRCA2-associated breast cancer. PLoS
Genet 2010, 6:e1001183.
11. Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L,
Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL,
Andrulis IL, Thomassen M, Gerdes AM, Caligo MA, Friedman E, Laitman Y,
Kaufman B, Paluch SS, Borg A, Karlsson P, Askmalm MS, Bustinza GB,
Nathanson K, Domchek SM, Rebbeck TR, Benitez J, Hamann U, et al:
Common variants of the BRCA1 wild-type allele modify the risk of
breast cancer in BRCA1 mutation carriers. Hum Mol Genet 2011,
20:4732-4747.
12. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS,
Apicella C, Smith LD, Hammet F, Southey MC, van ‘t Veer LJ, de Groot R,
Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A,
Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP,
Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Orsted DD,
et al: Low penetrance breast cancer susceptibility loci are associated
with specific breast tumour subtypes: findings from the Breast Cancer
Association Consortium. Hum Mol Genet 2011, 20:3289-3303.
13. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA,
Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G,
Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C,
Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P,
Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomaki K,
et al: Heterogeneity of breast cancer associations with five susceptibility
loci by clinical and pathological characteristics. PLoS Genet 2008, 4:
e1000054.
14. Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D,
Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB,
Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM,
Janavicius R, Hansen TV, Nielsen FC, Ejlertsen B, Osorio A, Munoz-Repeto I,
Duran M, Godino J, Pertesi M, Benitez J, Peterlongo P, Manoukian S,
Peissel B, Zaffaroni D, Cattaneo E, et al: Common breast cancer
susceptibility alleles are associated with tumour subtypes in BRCA1 and
BRCA2 mutation carriers: results from the Consortium of Investigators of
Modifiers of BRCA1/2. Breast Cancer Res 2011, 13:R110.
15. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S,
Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W,
Eccles D, Evans DG, Hooning M, Schutte M, van den Ouweland A,
Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM,
Rahman N, Easton DF: Genome-wide association study identifies five new
breast cancer susceptibility loci. Nat Genet 2010, 42:504-507.
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 17 of 18
16. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E,
Dennis J, Wang Q, Humphreys MK, Luccarini C, Baynes C, Conroy D,
Maranian M, Ahmed S, Driver K, Johnson N, Orr N, dos Santos Silva I,
Waisfisz Q, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Netherlands
Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON),
Hall P, Czene K, Irwanto A, Liu J, Nevanlinna H, Aittomäki K, Blomqvist C,
Meindl A, et al: Genome-wide association analysis identifies three new
breast cancer susceptibility loci. Nat Genet 2012.
17. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D,
Gut I, Heath S, Palles C, Coupland B, Broderick P, Schoemaker M, Jones M,
Williamson J, Chilcott-Burns S, Tomczyk K, Simpson G, Jacobs KB,
Chanock SJ, Hunter DJ, Tomlinson IP, Swerdlow A, Ashworth A, Ross G, dos
Santos Silva I, Lathrop M, Houlston RS, Peto J: Novel breast cancer
susceptibility locus at 9q31.2: results of a genome-wide association
study. J Natl Cancer Inst 2011, 103:425-435.
18. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M,
Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ,
Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR,
Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J,
Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A,
Lubinski J, Gronwald J, et al: RAD51 135G– > C modifies breast cancer
risk among BRCA2 mutation carriers: results from a combined analysis
of 19 studies. Am J Hum Genet 2007, 81:1186-1200.
19. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF,
Goldgar DE: An international initiative to identify genetic modifiers of
cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of
Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer
Res 2007, 9:104.
20. Lange K, Weeks D, Boehnke M: Programs for pedigree analysis: MENDEL,
FISHER, and dGENE. Genet Epidemiol 1988, 5:471-472.
21. Barnes D, Lee A, EMBRACE Investigators, kConFab Investigators, Easton D,
Antoniou AC: Evaluation of association methods for analysing modiers of
disease risk in carriers of high-risk mutations. Genet Epidemiol 2011.
22. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S,
Rennert HS, Narod SA: Clinical outcomes of breast cancer in carriers of
BRCA1 and BRCA2 mutations. N Engl J Med 2007, 357:115-123.
23. Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S: The 185delAG
mutation (c.68_69delAG) in the BRCA1 gene triggers translation
reinitiation at a downstream AUG codon. Hum Mutat 2006, 27:1024-1029.
24. Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM,
Lenoir GM: A BRCA1 nonsense mutation causes exon skipping. Am J
Hum Genet 1998, 62:713-715.
25. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S:
The nonsense-mediated mRNA decay pathway triggers degradation of
most BRCA1 mRNAs bearing premature termination codons. Hum Mol
Genet 2002, 11:2805-2814.
26. Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D,
Sinilnikova OM, Mazoyer S: Does the nonsense-mediated mRNA decay
mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53
proteins? Hum Mutat 2008, 29:65-73.
27. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA,
Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O,
Borg A, Passini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-
Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L,
Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, et al: The
BOADICEA model of genetic susceptibility to breast and ovarian cancers:
updates and extensions. Br J Cancer 2008, 98:1457-1466.
28. Boos DD: On generalised score tests. Am Stat 1992, 46:327-333.
29. Antoniou AC, Chenevix-Trench G: Common genetic variants and cancer
risk in Mendelian cancer syndromes. Curr Opin Genet Dev 2010,
20:299-307.
30. Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C,
Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin AK, Ambrosone C,
Winqvist R, Brauch H, Schmidt MK, Cox A, Cross SS, Sawyer E, Hartmann A,
Beckmann MW, Schulz-Wendtland R, Ekici AB, Tapper WJ, Gerty SM,
Durcan L, Graham N, Hein R, Nickels S, Flesch-Janys D, Heinz J, et al:
Common breast cancer susceptibility loci are associated with triple
negative breast cancer. Cancer Res 2011, 71:6240-6249.
31. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM,
Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, et al: A
parathyroid hormone-related protein implicated in malignant
hypercalcemia: cloning and expression. Science 1987, 237:893-896.
32. Asadi F, Kukreja S: Parathyroid hormone-related protein in prostate
cancer. Crit Rev Eukaryot Gene Expr 2005, 15:15-28.
33. Linforth R, Anderson N, Hoey R, Nolan T, Downey S, Brady G, Ashcroft L,
Bundred N: Coexpression of parathyroid hormone related protein and its
receptor in early breast cancer predicts poor patient survival. Clin Cancer
Res 2002, 8:3172-3177.
34. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J,
Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J,
Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A,
Hunter DJ, Hopper JL, Southey MC, Chanock SJ, Silva IS, Liu J, Eriksson L,
Couch FJ, Stone J, Apicella C, Czene K, et al: Common variants in ZNF365
are associated with both mammographic density and breast cancer risk.
Nat Genet 2011, 43:185-187.
35. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J,
Cook M, Warsi I, Evans DG, Eccles D, Douglas F, Paterson J, Hodgson S,
Izatt L, Cole T, Burgess L, Eeles R, Easton DF: Mammographic density and
breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res
2006, 66:1866-1872.
36. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-
Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ,
Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A,
Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W,
McGuire V, Whittemore AS, Campbell I, Gore ME, et al: Common variants at
19p13 are associated with susceptibility to ovarian cancer. Nat Genet
2010, 42:880-884.
37. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M,
Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ,
Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J,
Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C,
Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J,
Moysich KB, Goodman MT, et al: A genome-wide association study
identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat
Genet 2010, 42:874-879.
38. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-
Culver H, Chang-Claude J, Cramer DW, Dicioccio R, Dork T, Goode EL,
Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW,
Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM,
Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G,
et al: A genome-wide association study identifies a new ovarian cancer
susceptibility locus on 9p22.2. Nat Genet 2009, 41:996-1000.
39. Milne RL, Antoniou AC: Genetic modifiers of cancer risk for BRCA1 and
BRCA2 mutation carriers. Ann Oncol 2011, 22(Suppl 1):i11-i17.
doi:10.1186/bcr3121
Cite this article as: Antoniou et al.: Common variants at 12p11, 12q24,
9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for
BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research 2012 14:
R33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 18 of 18
